European Union regulators on Thursday recommended two new treatments against Covid-19 for use in the bloc.
The European Medicines Agency (EMA) said Kineret, an immunosuppressive produced by Swedish Orphan Biovitrum to treat inflammatory conditions, could "decrease lower airway damage, preventing development of severe respiratory failure".
It said also that GlaxoSmithKline's Xevudy drug had shown in a study that it "significantly reduces hospitalisation and deaths in patients with at least one underlying condition".
Kineret is already recommended by the EMA to treat various conditions, with the agency expanding its listing to cover Covid-19.
Its use is recommended for adults "with pneumonia requiring supplemental oxygen... who are at risk of developing severe respiratory failure", the EMA said in a statement.
Xevudy, developed by GSK with US firm Vir Biotechnology, is the third drug backed by the EMA that uses "monoclonal antibodies", which are proteins designed to attach to the spike protein of SARS-CoV-2, the virus that causes Covid.
The agency said Xevudy would be recommended for most patients aged 12 and above "who are at increased risk of the disease becoming severe".
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Apple Changes Its App Store Policy In EU After Probe TikTok Withdraws Rewards Feature From 'Lite' Version In France, Spain European Union Approves Humanitarian Aid To India Due To Recent Floods Nurse Raped, Killed On Way Home, Body Found 9 Days Later In UP "Don't Expect Anything From Me": Kolkata Hospital's New Principal Loses Cool Rahul Gandhi's Seat At Red Fort Triggers Fresh Congress Attack On BJP Left, BJP, Creating Unrest: Mamata Banerjee On Midnight Attack At Hospital 'Don't Club Us With Others,' Says Manipur's Thadou Tribe, Waits For Peace Plan More Monkey Pox Cases Likely To Hit Europe Soon, Says WHO Track Latest News Live on NDTV.com and get news updates from India and around the world.